<DOC>
	<DOC>NCT01461967</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, cross-over study will assess the safety, pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. In Part 1, subjects will be randomized to receive single ascending doses of either RO5508887 or placebo. In Part 2, subjects will receive a single dose of RO5508887 on two occasions, with or without food. Anticipated time on study is up to 12 weeks.</brief_summary>
	<brief_title>A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteers, 1845 (Part 1) or 1865 (Part 2) years of age inclusive; healthy status is defined by absence of evidence of any active or chronic disease Body Mass Index (BMI) 18 to 30 kg/m2 inclusive Male subjects must use a barrier method of contraception for the duration of the study and for 30 days after the last dose Suspicion of regular consumption of drugs of abuse Regular smoker (&gt;5 cigarettes, &gt;1 pipeful or &gt;1 cigar per day) Positive for hepatitis B, hepatitis C or HIV infection History of hypersensitivity or severe drug reaction Participation in an investigational drug or device study within three months before the first drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>